regulator of G protein signaling 22Genealiases: CT145 · PRTD-NY2
Q-omics provides the consensus-scored RGS22 profile across patient tissues and cancer cell-line models. RGS22 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RGS22 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RGS22 RNA expression shows 18,036 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, BLCA, and BRCA as cancer lineages where RGS22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS22 survival associations across molecular data types. RGS22 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS22 RNA expression–survival associations across cancer types. High RGS22 expression shows unfavorable associations in UVM, COAD, KICH and BLCA, but favorable associations in BRCA and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for RGS22 RNA expression.
This table summarizes RGS22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RGS22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS22 shows lower tumor expression in BLCA, KICH, COAD, LUAD, LUSC and THCA. The BLCA box plot shows higher RGS22 RNA expression in normal versus tumor tissue (log2 FC = −1.025, t-test p < 0.001).
This table shows molecular features associated with RGS22 in patient tissues and cancer cell lines. In patient samples, RGS22 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
